Characterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review

Acute generalized exanthematous pustulosis with erythema multiforme‐like lesions induced by Hydroxychloroquine in a woman with coronavirus disease 2019 (COVID‐19)

“…On follow-up, the lesions were persistent on the same locations without evolving to blistering. Surprisingly, in the work by Marzano et al, 4 reporting varicella-like lesions on COVID-19 patients, the histological image included in their report resembles our case.…”

“…2 HCQ is widely used to treat dermatologic and rheumatologic diseases, and it has been described as one of the main drugs triggering acute generalized exanthematous pustulosis (AGEP). 3,4 Only one single case of AGEP induced by HIV post-exposure prophylaxis with lopinavir/ritonavir has been reported. 5 Figure 2 Acral skin that shows an intra-epidermal vesicle.…”

A clinicopathological study of eight patients with COVID‐19 pneumonia and a late‐onset exanthema

“…9 Nevertheless, the incidence of this adverse effect to HCQ is infrequent. 10 Thus, if the type of exanthema we are describing here is related to HCQ, there may be another factors (as SARS-CoV-2 virus itself) playing a role.…”

Acute generalized exanthematous pustulosis after COVID ‐19 treatment with hydroxychloroquine

“…3,4 The latter is the most frequently reported serious side effect related to HCQ. 3 We would like to share our experience from Tunisia. As of April 26, 2020, there are 967 accumulated COVID-19 cases.…”